DOP2024000028A - Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos - Google Patents

Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos

Info

Publication number
DOP2024000028A
DOP2024000028A DO2024000028A DO2024000028A DOP2024000028A DO P2024000028 A DOP2024000028 A DO P2024000028A DO 2024000028 A DO2024000028 A DO 2024000028A DO 2024000028 A DO2024000028 A DO 2024000028A DO P2024000028 A DOP2024000028 A DO P2024000028A
Authority
DO
Dominican Republic
Prior art keywords
interleukin
receptor
therapeutic uses
degraders
kinases associated
Prior art date
Application number
DO2024000028A
Other languages
English (en)
Inventor
Lee John
Wu Jeffrey
Palmer Wylie
Ozboya Kerem
Kane Tim
Original Assignee
Gilead Sciences Inc
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Nurix Therapeutics Inc filed Critical Gilead Sciences Inc
Publication of DOP2024000028A publication Critical patent/DOP2024000028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente divulgación proporciona compuestos bifuncionales como degradadores de IRAK4 a través de la vía del proteasoma de ubiquitina, y método para tratar enfermedades moduladas por IRAK4.
DO2024000028A 2021-08-18 2024-02-14 Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos DOP2024000028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163234606P 2021-08-18 2021-08-18
PCT/US2022/040765 WO2023023255A1 (en) 2021-08-18 2022-08-18 Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof

Publications (1)

Publication Number Publication Date
DOP2024000028A true DOP2024000028A (es) 2024-04-15

Family

ID=83594510

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2024000028A DOP2024000028A (es) 2021-08-18 2024-02-14 Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos

Country Status (12)

Country Link
US (1) US11976071B2 (es)
EP (1) EP4367118A1 (es)
KR (1) KR20240048010A (es)
CN (1) CN117813307A (es)
AR (1) AR126826A1 (es)
AU (1) AU2022330009A1 (es)
CA (1) CA3226118A1 (es)
CO (1) CO2024001524A2 (es)
DO (1) DOP2024000028A (es)
IL (1) IL310446A (es)
TW (1) TW202315632A (es)
WO (1) WO2023023255A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117157298A (zh) * 2022-03-31 2023-12-01 石药集团中奇制药技术（石家庄）有限公司 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
EP1322750A4 (en) 2000-09-08 2004-09-29 California Inst Of Techn PROTEOLYSIC CHIMERAL PHARMACEUTICAL
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US9464326B2 (en) 2012-03-22 2016-10-11 University Of Maryland, Baltimore Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
EP3256470B1 (en) 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
WO2016210034A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
EP3368034A4 (en) 2015-10-29 2019-06-19 Children's Hospital Medical Center METHOD AND COMPOSITIONS FOR TREATMENT OF HEAD NECK CARCINOMA
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
AU2017341723B2 (en) 2016-10-11 2021-12-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3532164A4 (en) 2016-10-28 2020-10-07 Children's Hospital Medical Center TREATMENT OF DISEASES RELATED TO ACTIVATED IRAQ
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2018232288A1 (en) 2017-06-16 2018-12-20 Genentech, Inc. Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019103196A1 (ko) 2017-11-24 2019-05-31 엘지전자 주식회사 무선 통신 시스템에서 빔을 리포팅하는 방법 및 장치
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
AU2019220632B2 (en) 2018-02-14 2024-02-22 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
WO2020036830A1 (en) 2018-08-13 2020-02-20 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021067606A1 (en) 2019-10-01 2021-04-08 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
JP2023514323A (ja) * 2020-02-19 2023-04-05 ニューリックス セラピューティクス，インコーポレイテッド インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用
US20230322761A1 (en) 2020-03-11 2023-10-12 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EP4167728A1 (en) 2020-06-17 2023-04-26 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20230040991A (ko) 2020-06-19 2023-03-23 씨4 테라퓨틱스, 인코포레이티드 Braf 분해제
CA3217892A1 (en) 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use

Also Published As

Publication number Publication date
EP4367118A1 (en) 2024-05-15
TW202315632A (zh) 2023-04-16
CO2024001524A2 (es) 2024-02-26
CA3226118A1 (en) 2023-02-23
CN117813307A (zh) 2024-04-02
US11976071B2 (en) 2024-05-07
IL310446A (en) 2024-03-01
AU2022330009A1 (en) 2024-01-25
US20230120619A1 (en) 2023-04-20
AR126826A1 (es) 2023-11-15
KR20240048010A (ko) 2024-04-12
WO2023023255A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
DOP2024000028A (es) Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
CO2020015226A2 (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CO2021006672A2 (es) Moduladores de nlrp3
CO2019004945A2 (es) Inhibidores de la magl
CO2020010552A2 (es) Compuestos
CO6551740A2 (es) Derivados pirazólicos como moduladores de los canales de calcio activados por la liberación de calcio
CO2021011919A2 (es) Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes
AR089554A1 (es) Formas cristalinas de un inhibidor de la dipeptidil peptidasa-iv
CO2020001715A2 (es) Compuestos espirocíclicos y sus métodos de preparación y uso
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
CO2020001724A2 (es) Compuestos espirocíclicos y sus métodos de preparación y uso referencia cruzada
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CL2023001195A1 (es) Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades.
CL2017002846A1 (es) Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
UY34991A (es) Inhibidores de la beta-secretasa
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades